• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab.

作者信息

Zafiriou Efterpi, Karampinis Emmanouil, Papadopoulos Vasileios, Stefani Georgia, Kotsakis Athanasios, Vassilopoulos George

机构信息

Department of Dermatology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Larissa, Greece.

Department of Oncology, University General Hospital of Larissa, Larissa, Greece.

出版信息

Dermatol Pract Concept. 2025 Jan 30;15(1):4642. doi: 10.5826/dpc.1501a4642.

DOI:10.5826/dpc.1501a4642
PMID:40117636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11928117/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df54/11928117/7476e3453716/dc1501a4642g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df54/11928117/7476e3453716/dc1501a4642g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df54/11928117/7476e3453716/dc1501a4642g001.jpg

相似文献

1
Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab.真性红细胞增多症中的非黑色素瘤皮肤癌加重：由鲁索替尼引发并通过干扰素/西米普利单抗得以缓解
Dermatol Pract Concept. 2025 Jan 30;15(1):4642. doi: 10.5826/dpc.1501a4642.
2
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.MAJIC-PV研究中使用鲁索替尼治疗血癌真性红细胞增多症：通俗易懂的总结
Future Oncol. 2024 Dec;20(40):3365-3376. doi: 10.1080/14796694.2024.2406597. Epub 2024 Oct 1.
3
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.羟基脲耐药/不耐受的真性红细胞增多症患者接受芦可替尼或最佳可用疗法治疗后的主要临床结局的真实世界分析。
Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13.
4
Unexpected Neurological Symptoms of Ruxolitinib: A Case Report.鲁索替尼意外的神经学症状：一例报告
J Hematol. 2020 Dec;9(4):137-139. doi: 10.14740/jh642. Epub 2020 Oct 1.
5
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.一项关于芦可替尼与真性红细胞增多症和骨髓纤维化患者非黑色素瘤皮肤癌相关性的10年回顾性队列研究。
J Am Acad Dermatol. 2022 Feb;86(2):339-344. doi: 10.1016/j.jaad.2021.10.004. Epub 2021 Oct 11.
6
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.鲁索替尼在RESPONSE研究中与干扰素对比使用后的疗效及安全性。
Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.
7
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.芦可替尼在真性红细胞增多症患者的真实世界管理中的安全性和有效性：由 pH 阴性 MPN 拉丁美洲组进行的合作回顾性研究。
Ann Hematol. 2022 Jun;101(6):1275-1282. doi: 10.1007/s00277-022-04815-w. Epub 2022 Mar 22.
8
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination.病例报告：阿维鲁单抗与芦可替尼联合治疗真性红细胞增多症和继发性转移性默克尔细胞癌：一种可能成功的联合方案
Front Oncol. 2023 Jun 7;13:1212638. doi: 10.3389/fonc.2023.1212638. eCollection 2023.
9
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.接受 Janus 激酶抑制剂芦可替尼治疗真性红细胞增多症后出现侵袭性 Merkel 细胞癌。
In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.
10
Possible ruxolitinib-induced acquired epidermodysplasia verruciformis and multiple non-melanoma skin cancers in a patient with polycythemia vera.一名真性红细胞增多症患者可能因鲁索替尼诱发获得性疣状表皮发育不良和多发性非黑色素瘤皮肤癌。
J Cosmet Dermatol. 2022 Nov;21(11):6502-6503. doi: 10.1111/jocd.15253. Epub 2022 Aug 9.

引用本文的文献

1
Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature.与羟基脲相关的多发性皮肤癌：病例报告及文献综述
Cancer Rep (Hoboken). 2025 Aug;8(8):e70304. doi: 10.1002/cnr2.70304.

本文引用的文献

1
Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.将 PD-1/PD-L1 阻断与 I 型干扰素联合用于癌症治疗。
Front Immunol. 2023 Aug 24;14:1249330. doi: 10.3389/fimmu.2023.1249330. eCollection 2023.
2
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.一项关于芦可替尼与真性红细胞增多症和骨髓纤维化患者非黑色素瘤皮肤癌相关性的10年回顾性队列研究。
J Am Acad Dermatol. 2022 Feb;86(2):339-344. doi: 10.1016/j.jaad.2021.10.004. Epub 2021 Oct 11.